A
Alexis Desrichard
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 28
Citations - 8166
Alexis Desrichard is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Immune checkpoint. The author has an hindex of 21, co-authored 28 publications receiving 6238 citations. Previous affiliations of Alexis Desrichard include New York University & Columbia University.
Papers
More filters
Journal ArticleDOI
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder,Vladimir Makarov,Taha Merghoub,Jianda Yuan,Jesse M. Zaretsky,Alexis Desrichard,Logan A. Walsh,Michael A. Postow,Phillip Wong,Teresa S. Ho,Travis J. Hollmann,Cameron Bruggeman,Kasthuri Kannan,Yanyun Li,Ceyhan Elipenahli,Cailian Liu,Christopher T. Harbison,Lisu Wang,Antoni Ribas,Jedd D. Wolchok,Jedd D. Wolchok,Timothy A. Chan +21 more
TL;DR: In this paper, the authors provide clarification and correction to their article "Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma" (Dec. 4, 2014, issue).
Journal ArticleDOI
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz,Jonathan J. Havel,Vladimir Makarov,Alexis Desrichard,Walter J. Urba,Jennifer S. Sims,F. Stephen Hodi,Salvador Martín-Algarra,Rajarsi Mandal,William H. Sharfman,Shailender Bhatia,Wen-Jen Hwu,Thomas F. Gajewski,Craig L. Slingluff,Diego Chowell,Sviatoslav M. Kendall,Han Chang,Rachna Shah,Fengshen Kuo,Luc G. T. Morris,John-William Sidhom,Jonathan P. Schneck,Christine Horak,Nils Weinhold,Timothy A. Chan +24 more
TL;DR: Comprehensive genomic profiling data in this study provide insight into nivolumab's mechanism of action and reveal expansion of T cell clones in the setting of neoantigen loss.
Journal ArticleDOI
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli,Pamela L. Strissel,Alexis Desrichard,Huili Li,Christine Henke,Benjamin Akman,Alexander Hein,Neal S. Rote,Leslie Cope,Alexandra Snyder,Vladimir Makarov,Sadna Budhu,Dennis J. Slamon,Jedd D. Wolchok,Drew M. Pardoll,Matthias W. Beckmann,Cynthia A. Zahnow,Taha Merghoub,Timothy A. Chan,Stephen B. Baylin,Reiner Strick +20 more
TL;DR: In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Journal ArticleDOI
The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal,Yasin Senbabaoglu,Alexis Desrichard,Jonathan J. Havel,Martin G. Dalin,Nadeem Riaz,Ken-Wing Lee,Ian Ganly,A. Ari Hakimi,Timothy A. Chan,Luc G. T. Morris +10 more
TL;DR: HNSCC had the highest median Treg/CD8+ T cell ratio and the highest levels of CD56dim NK cell infiltration, in the authors' pan-cancer analysis of the most immune-infiltrated tumors, and this landscape provides a potentially novel rationale for investigation of agents targeting modulators of Tregs and NK cells in the treatment of advanced HNSCC.
Journal ArticleDOI
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G. T. Morris,Nadeem Riaz,Alexis Desrichard,Yasin Senbabaoglu,A. Ari Hakimi,Vladimir Makarov,Jorge S. Reis-Filho,Timothy A. Chan +7 more
TL;DR: A pan-cancer analysis of over 3300 tumors shows that ITH is a prognostic marker in multiple cancers, indicating that tumor heterogeneity represents a significant obstacle to cancer control.